Company: SION
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0002036042-25-000016
Chunk: 206

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 206
---
370,621 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024, respectively— 110,791 Series C convertible preferred stock, $0.001 par value, no shares and 18,628,970 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024, respectively— 181,328 Total convertible preferred stock— 330,368 Stockholders’ equity (deficit):Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of March 31, 2025 and December 31 2024, respectively; no shares issued or outstanding as of March 31, 2025 and December 31 2024— — Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of March 31, 2025 and December 31 2024, respectively; 44,124,394 and 4,798,721 shares issued, 44,092,117 and 4,722,763 shares outstanding as of March 31, 2025 and December 31, 2024, respectively44 5 Additional paid-in capital548,992 17,000 Accumulated other comprehensive income301 368 Accumulated deficit(197,568)(181,086)Total stockholders’ equity (deficit)351,769 (163,713)Total liabilities, convertible preferred stock and stockholders’ equity (deficit)$369,674 $185,752 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-2

Table of Contents

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(in thousands, except share and per share data) 

(Unaudited)

Three Months EndedMarch 31,20252024Operating expenses:Research and development$13,668 $10,220 General and administrative5,991 2,927 Total operating expenses19,659 13,147 Loss from operations(19,659)(13,147)Other income:Interest income3,000 1,132 Other income177 168 Total other income3,177 1,300 Net loss$(16,482)$(11